(S031) Dosimetric Analysis of Left-Sided Breast Cancer Treatment With Tomotherapy IMRT, IMRT, VMAT, and 3D-CRT

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Our analysis of this single-institution population of women with left-sided breast cancer treated to the whole breast demonstrates that differing radiation treatment techniques have statistically significant impacts on dosimetric parameters of the heart, left ventricle, and LAD.

Twisha Chakravarty, MD, Eugene C. Endres, Brent Parker, PhD, DABR, Sandra Hatch, MD; University of Texas Medical Branch

OBJECTIVES: Previous studies have demonstrated that the risk of ischemic heart disease is increased as a result of exposure to ionizing radiation in women treated for breast cancer. Alternative radiation techniques, such as intensity-modulated radiation therapy (IMRT), volumetric-modulated arc therapy (VMAT), and TomoTherapy IMRT, have been shown to improve dosimetric parameters of the heart and substructures. However, these techniques have not been compared with each other to potentially guide treatment decisions.

METHODS: Treatment plans from 10 patients treated to the whole breast for left-sided breast cancer in 2014 were collected. Treatment plans using TomoTherapy IMRT, IMRT, VMAT, and three-dimensional (3D) conformal radiation therapy with TomoDirect and opposed tangents were generated for each patient. Dosimetric parameters for the heart, left ventricle, and left anterior descending artery (LAD), including V2, V5, V10, Dmax, and mean doses, were collected and analyzed using paired t-test and analysis of variance (ANOVA).

RESULTS: For V2 of the LAD, no statistically significant difference was found between TomoTherapy IMRT and 3D conformal plans (67.2% vs 70.5% vs 75.0%; P = .49); however, TomoTherapy IMRT plans had significantly reduced V5 of the LAD when compared with 3D conformal plans, as well as IMRT and VMAT (2.0% vs range: 12.0–49.0%; P < .01). With regard to the heart and left ventricle, the V2 was significantly lower for 3D conformal plans vs TomoTherapy IMRT, VMAT, and IMRT (P < .01). This difference was maintained for V5 for the heart but not for the left ventricle. Across all three cardiac parameters, the average Dmax was significantly lower with TomoTherapy IMRT plans when compared with all other planning techniques (P < .01). 

CONCLUSIONS: Our analysis of this single-institution population of women with left-sided breast cancer treated to the whole breast demonstrates that differing radiation treatment techniques have statistically significant impacts on dosimetric parameters of the heart, left ventricle, and LAD. TomoTherapy IMRT was shown to be superior for reducing low-dose radiation to the LAD and maximum dose to all cardiac structures, particularly when compared with VMAT and IMRT. No significant difference was demonstrated in low-dose radiation exposure from treatment with TomoDirect vs opposed tangents. These results provide insight into treatment differences that may help guide clinical practice in the future, with an emphasis on reducing long-term patient toxicity. 

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
Related Content